8 hasil untuk "Massimo Morfini"
Menampilkan 1–8 · 1,63 detik · RSS
-
Artikel Jurnal
Pharmacokinetic characteristics of the triple inactivated plasma-derived Kedrion FIX concentrate: data from the KB037 clinical trial
The pharmacokinetics data of phase I/II clinical trials (EudraCT Number: 2005-006186-14) of the new, triple inactivated plasma-derived Kedrion FIX concentrate was designed according to the recommendations of SSC-ISTH [1,2]: 11 post-infusion FIX/time points samples during the first 72 h. The PK data…
-
Artikel Jurnal
Pharmacokinetics of extended half-life albumin-fused factor IX and heterogeneous F9 variants in hemophilia B: a retrospective cohort study
No information is available about the influence exerted by F9 variants on extended half-life (EHL)-recombinant factor IX (rFIX) pharmacokinetics (PK). Adult patients with severe HB (n=41), infused with EHL albumin-fused-rIX-FP, were investigated for key parameters, obtained by Non-Compartmental…
-
Artikel Jurnal Teks lengkap
Managing Relevant Clinical Conditions of Hemophilia A/B Patients
The Medical Directors of nine Italian Hemophilia Centers reviewed and discussed the key issues concerning the replacement therapy of hemophilia patients during a one-day consensus conference held in Rome one year ago. Particular attention was paid to the replacement therapy needed for surgery using…
-
Artikel Jurnal
Clinical use of Haemate® P in inherited von Willebrand’s disease: a cohort study on 100 Italian patients
Background and Objectives Plasma-derived concentrates containing von Willebrand factor and factor VIII (VWF/FVIII concentrates) are the mainstay of treatment of patients with inherited von Willebrand’s disease (VWD) who are unresponsive or have a contraindication to desmopressin (DDAVP) therapy…
-
Artikel Jurnal Teks lengkap
Personalized Prophylaxis with myPKFiTCE: A Real-World Cost-Effectiveness Analysis in Haemophilia A Patients
Background and Objectives: This study aimed to assess the effectiveness and costs associated with pharmacokinetics-driven (PK) prophylaxis based on the myPKFiT® device in patients affected by hemophilia A (HA) in Italy. Materials and Methods: An observational retrospective study was conducted in…
-
Artikel Jurnal
The expert in hemostasis and thrombosis in the Italian health system: role and requirements for a specific clinical and laboratory expertise
Hemorrhagic and thrombotic diseases are highly heterogeneous disorders that may affect a large proportion of the population, as in the case of patients taking antithrombotic drugs. The appropriate management of such conditions requires the availability of specific diagnostic assays, together with…
-
Artikel Jurnal Teks lengkap
Identification of the Profile of the Patients with Hemophilia B Eligible for Treatment with Nonacog Alfa Once-Weekly
This study aimed to identify the characteristics of patients with hemophilia B eligible for once-weekly treatment with Nonacog alfa. Methods: A survey was conducted in 14 Hemophilia (HCs) of Italy. These centers were given a questionnaire consisting of ten closed multiple-choice questions. The…
-
Artikel Jurnal
The Italian AICE-Genetics hemophilia A database: results and correlation with clinical phenotype
Background The high mutational heterogeneity of hemophilia A is a challenge for the provision of genetic services. We plan to identify the mutation in patients with hemophilia A in order to create a confidential national database of mutations for the optimization of genetic services in Italy.Design…